{"entity":{"type":"insider","cik":"0001388773","url":"/insider/0001388773","json_url":"/insider/0001388773.json","name":"Clague Laura","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":40,"n_filings":24,"first":"2008-12-15","last":"2022-05-12","span_basis":"filed_date"},"name_variants":[{"name":"Clague Laura","source":"filing","n_filings":24,"first_seen":"2008-12-15","last_seen":"2022-05-12"}],"transactions":[{"id":6455485,"accession":"0001209191-22-028707","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-028707","line_url":"/filing/0001209191-22-028707#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1375.0,"shares_display":"1,375","price_per_share":21.51,"price_display":"21.51","price_state":"stated","total_value":29576.25,"total_display":"29,576.25","total_whole":"29,576","shares_owned_after":35655.0,"shares_owned_after_display":"35,655","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-11","filed_date":"2022-05-12","scope":"insider"},{"id":6455481,"accession":"0001209191-22-028707","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-028707","line_url":"/filing/0001209191-22-028707#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":825.0,"shares_display":"825","price_per_share":21.51,"price_display":"21.51","price_state":"stated","total_value":17745.75,"total_display":"17,745.75","total_whole":"17,746","shares_owned_after":37030.0,"shares_owned_after_display":"37,030","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-10","filed_date":"2022-05-12","scope":"insider"},{"id":6868955,"accession":"0001437749-22-004289","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-22-004289","line_url":"/filing/0001437749-22-004289#line-2","is_derivative":false,"issuer_cik":"0000924383","issuer_name":"Genasys Inc.","issuer_ticker":"GNSS","issuer_name_source":null,"issuer_url":"/issuer/0000924383","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13716.0,"shares_display":"13,716","price_per_share":3.14,"price_display":"3.14","price_state":"stated","total_value":43068.24,"total_display":"43,068.24","total_whole":"43,068","shares_owned_after":204311.0,"shares_owned_after_display":"204,311","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-23","filed_date":"2022-02-24","scope":"insider"},{"id":6272043,"accession":"0001209191-22-006362","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-006362","line_url":"/filing/0001209191-22-006362#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1238.0,"shares_display":"1,238","price_per_share":27.4,"price_display":"27.40","price_state":"stated","total_value":33921.2,"total_display":"33,921.20","total_whole":"33,921","shares_owned_after":37855.0,"shares_owned_after_display":"37,855","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-02","scope":"insider"},{"id":6344511,"accession":"0001209191-22-005080","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-005080","line_url":"/filing/0001209191-22-005080#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2063.0,"shares_display":"2,063","price_per_share":24.98,"price_display":"24.98","price_state":"stated","total_value":51533.74,"total_display":"51,533.74","total_whole":"51,534","shares_owned_after":29253.0,"shares_owned_after_display":"29,253","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-24","filed_date":"2022-01-26","scope":"insider"},{"id":6605878,"accession":"0001209191-22-003046","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-003046","line_url":"/filing/0001209191-22-003046#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":27.4,"price_display":"27.40","price_state":"stated","total_value":205500.0,"total_display":"205,500.00","total_whole":"205,500","shares_owned_after":31316.0,"shares_owned_after_display":"31,316","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-12","scope":"insider"},{"id":5000879,"accession":"0001209191-21-052077","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-052077","line_url":"/filing/0001209191-21-052077#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1407.0,"shares_display":"1,407","price_per_share":17.1182,"price_display":"17.12","price_state":"stated","total_value":24085.3074,"total_display":"24,085.31","total_whole":"24,085","shares_owned_after":31316.0,"shares_owned_after_display":"31,316","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-17","filed_date":"2021-08-17","scope":"insider"},{"id":5425186,"accession":"0001209191-21-032314","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-032314","line_url":"/filing/0001209191-21-032314#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":19.46,"price_display":"19.46","price_state":"stated","total_value":38920.0,"total_display":"38,920.00","total_whole":"38,920","shares_owned_after":28223.0,"shares_owned_after_display":"28,223","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-12","filed_date":"2021-05-13","scope":"insider"},{"id":5425182,"accession":"0001209191-21-032314","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-032314","line_url":"/filing/0001209191-21-032314#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":19.14,"price_display":"19.14","price_state":"stated","total_value":38280.0,"total_display":"38,280.00","total_whole":"38,280","shares_owned_after":30223.0,"shares_owned_after_display":"30,223","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-13","scope":"insider"},{"id":4915949,"accession":"0001437749-21-005857","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-21-005857","line_url":"/filing/0001437749-21-005857#line-2","is_derivative":false,"issuer_cik":"0000924383","issuer_name":"Genasys Inc.","issuer_ticker":"GNSS","issuer_name_source":null,"issuer_url":"/issuer/0000924383","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5456.0,"shares_display":"5,456","price_per_share":7.4166,"price_display":"7.42","price_state":"stated","total_value":40464.9696,"total_display":"40,464.97","total_whole":"40,465","shares_owned_after":170144.0,"shares_owned_after_display":"170,144","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-10","filed_date":"2021-03-12","scope":"insider"},{"id":4222532,"accession":"0001209191-21-008802","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-008802","line_url":"/filing/0001209191-21-008802#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2250.0,"shares_display":"2,250","price_per_share":31.58,"price_display":"31.58","price_state":"stated","total_value":71055.0,"total_display":"71,055.00","total_whole":"71,055","shares_owned_after":32223.0,"shares_owned_after_display":"32,223","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-09","scope":"insider"},{"id":4222527,"accession":"0001209191-21-008802","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-008802","line_url":"/filing/0001209191-21-008802#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2250.0,"shares_display":"2,250","price_per_share":31.41,"price_display":"31.41","price_state":"stated","total_value":70672.5,"total_display":"70,672.50","total_whole":"70,673","shares_owned_after":34473.0,"shares_owned_after_display":"34,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-09","scope":"insider"},{"id":4257880,"accession":"0001209191-21-007632","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-007632","line_url":"/filing/0001209191-21-007632","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3625.0,"shares_display":"3,625","price_per_share":28.91,"price_display":"28.91","price_state":"stated","total_value":104798.75,"total_display":"104,798.75","total_whole":"104,799","shares_owned_after":33348.0,"shares_owned_after_display":"33,348","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-03","filed_date":"2021-02-03","scope":"insider","n_lines":2},{"id":4881772,"accession":"0001209191-21-007024","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-007024","line_url":"/filing/0001209191-21-007024","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3625.0,"shares_display":"3,625","price_per_share":30.75,"price_display":"30.75","price_state":"stated","total_value":111468.75,"total_display":"111,468.75","total_whole":"111,469","shares_owned_after":36973.0,"shares_owned_after_display":"36,973","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-02","scope":"insider","n_lines":2},{"id":3132009,"accession":"0001209191-20-060591","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-060591","line_url":"/filing/0001209191-20-060591#line-3","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":22.72,"price_display":"22.72","price_state":"stated","total_value":85200.0,"total_display":"85,200.00","total_whole":"85,200","shares_owned_after":19473.0,"shares_owned_after_display":"19,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-25","filed_date":"2020-11-25","scope":"insider"},{"id":3132006,"accession":"0001209191-20-060591","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-060591","line_url":"/filing/0001209191-20-060591#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":23.86,"price_display":"23.86","price_state":"stated","total_value":89475.0,"total_display":"89,475.00","total_whole":"89,475","shares_owned_after":23223.0,"shares_owned_after_display":"23,223","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-24","filed_date":"2020-11-25","scope":"insider"},{"id":2225661,"accession":"0001209191-20-058945","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-058945","line_url":"/filing/0001209191-20-058945#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":23.975,"price_display":"23.98","price_state":"stated","total_value":179812.5,"total_display":"179,812.50","total_whole":"179,813","shares_owned_after":19473.0,"shares_owned_after_display":"19,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-17","scope":"insider"},{"id":2295064,"accession":"0001209191-20-058417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-058417","line_url":"/filing/0001209191-20-058417#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":23.6095,"price_display":"23.61","price_state":"stated","total_value":177071.25,"total_display":"177,071.25","total_whole":"177,071","shares_owned_after":26973.0,"shares_owned_after_display":"26,973","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-13","filed_date":"2020-11-13","scope":"insider"},{"id":2248469,"accession":"0001209191-20-051732","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-051732","line_url":"/filing/0001209191-20-051732#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":18.48,"price_display":"18.48","price_state":"stated","total_value":27720.0,"total_display":"27,720.00","total_whole":"27,720","shares_owned_after":19473.0,"shares_owned_after_display":"19,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-23","filed_date":"2020-09-23","scope":"insider"},{"id":2796900,"accession":"0001209191-20-051612","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-051612","line_url":"/filing/0001209191-20-051612#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":18.59,"price_display":"18.59","price_state":"stated","total_value":27885.0,"total_display":"27,885.00","total_whole":"27,885","shares_owned_after":20973.0,"shares_owned_after_display":"20,973","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-22","filed_date":"2020-09-22","scope":"insider"},{"id":2218878,"accession":"0001209191-20-029022","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-029022","line_url":"/filing/0001209191-20-029022","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1777.0,"shares_display":"1,777","price_per_share":17.107893134496344,"price_display":"17.11","price_state":"stated","total_value":30400.7261,"total_display":"30,400.73","total_whole":"30,401","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-12","filed_date":"2020-05-13","scope":"insider","n_lines":2},{"id":2218871,"accession":"0001209191-20-029022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-029022","line_url":"/filing/0001209191-20-029022#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1250.0,"shares_display":"1,250","price_per_share":14.95,"price_display":"14.95","price_state":"stated","total_value":18687.5,"total_display":"18,687.50","total_whole":"18,688","shares_owned_after":21250.0,"shares_owned_after_display":"21,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-11","filed_date":"2020-05-13","scope":"insider"},{"id":3255832,"accession":"0001209191-20-018647","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-018647","line_url":"/filing/0001209191-20-018647#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":15.02,"price_display":"15.02","price_state":"stated","total_value":60080.0,"total_display":"60,080.00","total_whole":"60,080","shares_owned_after":22500.0,"shares_owned_after_display":"22,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-10","filed_date":"2020-03-12","scope":"insider"},{"id":8675795,"accession":"0001209191-19-030660","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-030660","line_url":"/filing/0001209191-19-030660#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1250.0,"shares_display":"1,250","price_per_share":18.71,"price_display":"18.71","price_state":"stated","total_value":23387.5,"total_display":"23,387.50","total_whole":"23,388","shares_owned_after":13500.0,"shares_owned_after_display":"13,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-16","scope":"insider"},{"id":8675793,"accession":"0001209191-19-030660","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-030660","line_url":"/filing/0001209191-19-030660#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1250.0,"shares_display":"1,250","price_per_share":17.78,"price_display":"17.78","price_state":"stated","total_value":22225.0,"total_display":"22,225.00","total_whole":"22,225","shares_owned_after":14750.0,"shares_owned_after_display":"14,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-15","filed_date":"2019-05-16","scope":"insider"},{"id":8450888,"accession":"0001209191-19-009925","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-009925","line_url":"/filing/0001209191-19-009925#line-2","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1016.0,"shares_display":"1,016","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":21844.0,"total_display":"21,844.00","total_whole":"21,844","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-12","filed_date":"2019-02-13","scope":"insider"},{"id":8450883,"accession":"0001209191-19-009925","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-009925","line_url":"/filing/0001209191-19-009925#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1017.0,"shares_display":"1,017","price_per_share":21.38,"price_display":"21.38","price_state":"stated","total_value":21743.46,"total_display":"21,743.46","total_whole":"21,743","shares_owned_after":11016.0,"shares_owned_after_display":"11,016","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-11","filed_date":"2019-02-13","scope":"insider"},{"id":6297084,"accession":"0001209191-18-064021","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-064021","line_url":"/filing/0001209191-18-064021","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":21.829388,"price_display":"21.83","price_state":"stated","total_value":81860.205,"total_display":"81,860.20","total_whole":"81,860","shares_owned_after":12933.0,"shares_owned_after_display":"12,933","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-21","filed_date":"2018-12-21","scope":"insider","n_lines":2},{"id":6297078,"accession":"0001209191-18-064021","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-064021","line_url":"/filing/0001209191-18-064021#line-1","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":22.0812,"price_display":"22.08","price_state":"stated","total_value":82804.5,"total_display":"82,804.50","total_whole":"82,805","shares_owned_after":15783.0,"shares_owned_after_display":"15,783","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-20","filed_date":"2018-12-21","scope":"insider"},{"id":6765893,"accession":"0001209191-18-059064","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-059064","line_url":"/filing/0001209191-18-059064","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":24.311211066666665,"price_display":"24.31","price_state":"stated","total_value":91167.0415,"total_display":"91,167.04","total_whole":"91,167","shares_owned_after":12824.0,"shares_owned_after_display":"12,824","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-15","filed_date":"2018-11-16","scope":"insider","n_lines":2},{"id":6765884,"accession":"0001209191-18-059064","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-059064","line_url":"/filing/0001209191-18-059064","is_derivative":false,"issuer_cik":"0001388773","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001388773","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":23.72545866666667,"price_display":"23.73","price_state":"stated","total_value":88970.47,"total_display":"88,970.47","total_whole":"88,970","shares_owned_after":16183.0,"shares_owned_after_display":"16,183","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-14","filed_date":"2018-11-16","scope":"insider","n_lines":2},{"id":4256566,"accession":"0001437749-13-011713","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-13-011713","line_url":"/filing/0001437749-13-011713#line-2","is_derivative":false,"issuer_cik":"0000924383","issuer_name":"LRAD Corp","issuer_ticker":"LRAD","issuer_name_source":null,"issuer_url":"/issuer/0000924383","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9400.0,"shares_display":"9,400","price_per_share":1.54,"price_display":"1.54","price_state":"stated","total_value":14476.0,"total_display":"14,476.00","total_whole":"14,476","shares_owned_after":22600.0,"shares_owned_after_display":"22,600","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-09-04","filed_date":"2013-09-06","scope":"insider"},{"id":3156095,"accession":"0001181431-08-067480","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-08-067480","line_url":"/filing/0001181431-08-067480","is_derivative":false,"issuer_cik":"0000924383","issuer_name":"AMERICAN TECHNOLOGY CORP /DE/","issuer_ticker":"ATCO","issuer_name_source":null,"issuer_url":"/issuer/0000924383","owner_cik":"0001388773","owner_name":"Clague Laura","owner_display_name":"Clague Laura","owner_url":"/insider/0001388773","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":0.435,"price_display":"0.44","price_state":"stated","total_value":870.0,"total_display":"870.00","total_whole":"870","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-12-11","filed_date":"2008-12-15","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":40,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":38,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":40},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001438533","name":"Travere Therapeutics, Inc.","url":"/issuer/0001438533","role":"Officer (Chief Financial Officer)","n_filings":20,"first_seen":"2018-11-16","last_seen":"2022-05-12"},{"type":"issuer","type_label":"ISSUER","cik":"0000924383","name":"Genasys Inc.","url":"/issuer/0000924383","role":"Director","n_filings":4,"first_seen":"2008-12-15","last_seen":"2022-02-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001388773","retrieved_at":"2026-08-22T06:28:26+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}